Tag: clinical trials
-
Trial Testing Diabetes Drug as Parkinson’s Treatment
A clinical trial has started to test a current drug for type 2 diabetes as a treatment for Parkinson’s disease.
-
Orphan Status Granted for Hemophilia Genome Editing
Treatments using genome-editing techniques for hemophilia B, a rare blood clotting disease, received orphan therapy status from the U.S. Food and Drug Administration.
-
Takeda Awarded $19.8 Million for Zika Vaccine
Takeda Pharmaceutical Company is receiving $19.8 million from a U.S. public health agency for initial steps to develop a vaccine to prevent Zika infections.
-
Trial Shows Antibody Slows Alzheimer’s Cognitive Decline
A clinical trial shows older individuals with early or mild cases of Alzheimer’s disease treated for a year with an engineered human antibody have less decline in mental functions associated with Alzheimer’s disease.
-
University Spin-Off Developing Sepsis Drug
A spin-off enterprise from University of British Columbia is licensing a cholesterol-lowering drug from drug maker Novartis to develop a treatment for sepsis and other severe infections.
-
Stem Cells, Engineered Protein Reverse Stroke Damage
A combination of stem cells and synthetic human protein was shown in lab mice to repair damaged brain cells a week after an induced stroke.
-
FDA Giving Fast-Track Review to Alzheimer’s Candidate
U.S. Food and Drug Administration is giving an accelerated review to a candidate drug designed to treat Alzheimer’s disease by reducing the toxicity of amyloid beta proteins making up the plaque accumulating in the brain.
-
PhRMA: 258 Vaccines in Clinical Development
An industry group of American pharmaceutical makers says its companies have 258 vaccines, including immunotherapies, in clinical trials or awaiting FDA approval.
-
Leukemia Drug Shows Potential as Heart Attack Therapy
A new drug being tested as a leukemia treatment was shown in lab mice to reduce inflammatory white blood cells that lead to a build-up of arterial plaques and heart disease.
-
Patent Advances for Gut Damage Treatment Delivery
A developer of therapies for damage to an intestinal barrier received a notice that the U.S. intends to issue a patent protecting the technology to deliver the treatments.